Literature DB >> 27491428

Molecular mechanisms involved in dendritic cell dysfunction in cancer.

Michael Tang1, Jun Diao1, Mark S Cattral2,3.   

Abstract

Dendritic cells (DC) play a pivotal role in the tumor microenvironment (TME). As the primary antigen-presenting cells in the tumor, DCs modulate anti-tumor responses by regulating the magnitude and duration of infiltrating cytotoxic T lymphocyte responses. Unfortunately, due to the immunosuppressive nature of the TME, as well as the inherent plasticity of DCs, tumor DCs are often dysfunctional, a phenomenon that contributes to immune evasion. Recent progresses in our understanding of tumor DC biology have revealed potential molecular targets that allow us to improve tumor DC immunogenicity and cancer immunotherapy. Here, we review the molecular mechanisms that drive tumor DC dysfunction. We discuss recent advances in our understanding of tumor DC ontogeny, tumor DC subset heterogeneity, and factors in the tumor microenvironment that affect DC recruitment, differentiation, and function. Finally, we describe potential strategies to optimize tumor DC function in the context of cancer therapy.

Entities:  

Keywords:  Checkpoint inhibitors; DC dysfunction; Danger-associated molecular patterns; Inflammation; Myeloid cells; Suppressor cells; Toll-like receptors; Transcription factors; Tumor immunity; Tumor-derived factors; Versican

Mesh:

Year:  2016        PMID: 27491428     DOI: 10.1007/s00018-016-2317-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  210 in total

1.  Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery.

Authors:  Rona M MacKie; Robin Reid; Brian Junor
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

2.  Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer.

Authors:  Arko Gorter; Henry J Zijlmans; Hestia van Gent; J Baptist Trimbos; Gert J Fleuren; Ekaterina S Jordanova
Journal:  Mod Pathol       Date:  2010-08-20       Impact factor: 7.842

3.  Subversion of anticancer immunosurveillance by radiotherapy.

Authors:  Laurence Zitvogel; Guido Kroemer
Journal:  Nat Immunol       Date:  2015-10       Impact factor: 25.606

4.  Cross-presentation by intercellular peptide transfer through gap junctions.

Authors:  Joost Neijssen; Carla Herberts; Jan Wouter Drijfhout; Eric Reits; Lennert Janssen; Jacques Neefjes
Journal:  Nature       Date:  2005-03-03       Impact factor: 49.962

5.  Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.

Authors:  G V Shurin; M R Shurin; S Bykovskaia; J Shogan; M T Lotze; E M Barksdale
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

Review 6.  Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?

Authors:  Cornelis J M Melief
Journal:  Eur J Immunol       Date:  2003-10       Impact factor: 5.532

7.  Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation.

Authors:  Nathalie E Blachère; Robert B Darnell; Matthew L Albert
Journal:  PLoS Biol       Date:  2005-04-26       Impact factor: 8.029

8.  Mesothelioma tumor cells modulate dendritic cell lipid content, phenotype and function.

Authors:  Joanne K Gardner; Cyril D S Mamotte; Priya Patel; Teong Ling Yeoh; Connie Jackaman; Delia J Nelson
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

9.  Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody.

Authors:  Alain P Vicari; Claudia Chiodoni; Céline Vaure; Smina Aït-Yahia; Christophe Dercamp; Fabien Matsos; Olivier Reynard; Catherine Taverne; Philippe Merle; Mario P Colombo; Anne O'Garra; Giorgio Trinchieri; Christophe Caux
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

10.  Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs.

Authors:  Jodi McGill; Nico Van Rooijen; Kevin L Legge
Journal:  J Exp Med       Date:  2008-07-07       Impact factor: 14.307

View more
  39 in total

Review 1.  Dendritic cells in cancer: the role revisited.

Authors:  Filippo Veglia; Dmitry I Gabrilovich
Journal:  Curr Opin Immunol       Date:  2017-02-10       Impact factor: 7.486

Review 2.  Danger-Associated Molecular Patterns Derived From the Extracellular Matrix Provide Temporal Control of Innate Immunity.

Authors:  Charles W Frevert; Jessica Felgenhauer; Malgorzata Wygrecka; Madalina V Nastase; Liliana Schaefer
Journal:  J Histochem Cytochem       Date:  2018-01-01       Impact factor: 2.479

Review 3.  Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity.

Authors:  Athanasios Papadas; Garrett Arauz; Alexander Cicala; Joshua Wiesner; Fotis Asimakopoulos
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 4.  Matrix proteoglycans in tumor inflammation and immunity.

Authors:  Gauri Deb; Alexander Cicala; Athanasios Papadas; Fotis Asimakopoulos
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-25       Impact factor: 5.282

Review 5.  Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.

Authors:  Azam Bozorgi; Maryam Bozorgi; Mozafar Khazaei
Journal:  Cell Oncol (Dordr)       Date:  2022-08-09       Impact factor: 7.051

Review 6.  Defining the versican interactome in lung health and disease.

Authors:  Fengying Tang; Jourdan E Brune; Mary Y Chang; Stephen R Reeves; William A Altemeier; Charles W Frevert
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-01       Impact factor: 5.282

Review 7.  The 'Danse Macabre'-Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes.

Authors:  Sara Hadjigol; Bansari A Shah; Neil M O'Brien-Simpson
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

8.  [Blocking programmed death-ligand 1 attenuates maturation inhibition of dendritic cells by co-cultured breast cancer cells].

Authors:  Xiao-Ran Yu; Qiao-Sheng Wen; Yi Xiao; Rui Tang; Fu-Xi Li; Wen-Feng Shao; Yan-Lin Yu; Jing-Bo Xiong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-05-20

9.  Tumor Dendritic Cells (DCs) Derived from Precursors of Conventional DCs Are Dispensable for Intratumor CTL Responses.

Authors:  Jun Diao; Hongtao Gu; Michael Tang; Jun Zhao; Mark S Cattral
Journal:  J Immunol       Date:  2018-07-11       Impact factor: 5.422

Review 10.  Immune crosstalk in cancer progression and metastatic spread: a complex conversation.

Authors:  Hannah Garner; Karin E de Visser
Journal:  Nat Rev Immunol       Date:  2020-02-05       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.